SNOA ערך בספרים למניה sonomapharma.com

Sonoma Pharmaceuticals develops antibacterial skin products, leveraging global sales across Europe and America. The change in book value per share on the GURU.Markets chart reflects a struggle for customer loyalty amid intense pressure from retail chains, where 1.38 is the current metric level. Business stability is supported by streamlined logistics channels and efficient hubs.

The stability of the Microcyn technology and the partner network of Sonoma Pharmaceuticals (SNOA) is reflected in the dynamics of net assets distributed across the number of shares outstanding. By analyzing accounting data on the book value per share, an investor can see the real tangible value of the business net of liabilities, which allows for an assessment of the efficiency of capitalizing profits into assets and the determination of the company's intrinsic cost of capital.